HB-adMSCs

Phase 2Biologic

HB-adMSCs is one of 355 biologic programs targeting Chronic Inflammatory Demyelinating Polyneuropathy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

354

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Inflammatory Demyelinating PolyneuropathyActive, not recruiting

Systemic Lupus ErythematosusActive, not recruiting

Cerebral PalsyActive, not recruiting

Muscular DystrophyActive, not recruiting

StrokeActive, not recruiting

Amyotrophic Lateral SclerosisActive, not recruiting

EncephalopathyActive, not recruiting

Pancreatic CancerActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Multiple SclerosisActive, not recruiting

Chronic Inflammatory Demyelinating PolyneuropathyPreclinical

Active, not recruiting

Systemic Lupus ErythematosusPreclinical

Active, not recruiting

Cerebral PalsyPreclinical

Active, not recruiting

Muscular DystrophyPreclinical

Active, not recruiting

StrokePreclinical

Active, not recruiting

Amyotrophic Lateral SclerosisPreclinical

Active, not recruiting

EncephalopathyPhase 1/Phase 2

Active, not recruiting

Pancreatic CancerPreclinical

Active, not recruiting

Rheumatoid ArthritisPhase 1/Phase 2

Active, not recruiting

Multiple SclerosisPhase 2

Active, not recruiting

Showing 10 of 13 indications

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

HB-adMSCs

HHope Biosciences Research Foundation

Phase 2

4 2

Stivarga

Bayer

Preclinical

1 3

Aimovig

Amgen

Preclinical

1 4

Activella

Eli Lilly

Preclinical

—5

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 6

Piperacillin/tazobactam

Pfizer

Preclinical

1 7

Nadroparin

GSK

Preclinical

1 8

Biological Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 9

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

1 10

Tpa

UUniversity of Florida

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

COVID-194 trials

Intermediate Size Expanded Access Protocol for the Treatment of Post-COVID-19 Syndrome

No longer available·HHope Biosciences Research Foundation··NCT04798066

A Clinical Trial to Determine the Safety and Efficacy of HB-adMSCs to Provide Protection Against COVID-19

Completed·HHope Biosciences Research Foundation·Phase 2·NCT04349631·51 enrolled

Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome

Completed·HHope Biosciences Research Foundation·Phase 2·NCT05126563·79 enrolled

Show 1 more trial

A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs Against COVID-19.

Completed·HHope Biosciences Research Foundation·Phase 2·NCT04348435·53 enrolled

Parkinson's Disease2 trials

Intermediate Size Patient Population Expanded Access IND for the Treatment of Patients With Parkinson's Disease.

No longer available·HHope Biosciences Research Foundation··NCT04772378

Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate)

Completed·HHope Biosciences Research Foundation·Phase 2·NCT04928287·24 enrolled

Polyneuropathy1 trial

Individual Patient Expanded Access IND to Treat Polyneuropathy

No longer available·HHope Biosciences Research Foundation··NCT04064983

ESS1 trial

"Individual Patient Expanded Access IND to Treat Primary Lateral Sclerosis"

No longer available·HHope Biosciences Research Foundation··NCT04825613

Pancreatic Cancer1 trial

Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer

No longer available·HHope Biosciences LLC··NCT04087889

12 more indications

Muscular Dystrophy1 trial

HBCMD01- Expanded Access for the Treatment of Congenital Muscular Dystrophy.

No longer available·HHope Biosciences Research Foundation··NCT05154851

Systemic Lupus Erythematosus1 trial

Individual Patient Expanded Access IND of Autologous HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE)

No longer available·HHope Biosciences Research Foundation··NCT04907175

Mesenchymal Stem Cells1 trial

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Treatment of SCI

No longer available·HHope Biosciences LLC··NCT03925649

Stroke1 trial

Individual Patient Expanded Access IND for the Treatment of Stroke

No longer available·HHope Biosciences Research Foundation··NCT04907188

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

An Expanded Access IND for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

No longer available·HHope Biosciences Research Foundation··NCT04825626

Encephalopathy1 trial

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy

Completed·HHope Biosciences LLC·Phase 1/2·NCT04063215·24 enrolled

Multiple Sclerosis1 trial

Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis

Completed·HHope Biosciences Research Foundation·Phase 2·NCT05116540·24 enrolled

Mesenchymal Stem Cell1 trial

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer's Disease

Withdrawn·HHope Biosciences LLC·Phase 1/2·NCT04228666

Cerebral Palsy1 trial

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral Palsy

No longer available·HHope Biosciences Research Foundation··NCT04029896

Spinal Cord Injury1 trial

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Spinal Cord Injury

No longer available·HHope Biosciences Research Foundation··NCT04064957

Amyotrophic Lateral Sclerosis1 trial

Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral Sclerosis

No longer available·HHope Biosciences Research Foundation··NCT04514952

Rheumatoid Arthritis1 trial

Phase 1/2a Clinical Trial to Assess the Safety of HB-adMSCs for the Treatment of Rheumatoid Arthritis

Completed·HHope Biosciences LLC·Phase 1/2·NCT03691909·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 21 trial records for HB-adMSCs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HB-adMSCs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HB-adMSCs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hope Biosciences Research Foundation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: HHope Biosciences Research Foundation

HB-adMSCs

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

COVID-194 trials

Parkinson's Disease2 trials

Polyneuropathy1 trial

ESS1 trial

Pancreatic Cancer1 trial

Muscular Dystrophy1 trial

Systemic Lupus Erythematosus1 trial

Mesenchymal Stem Cells1 trial

Stroke1 trial

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

Encephalopathy1 trial

Multiple Sclerosis1 trial

Mesenchymal Stem Cell1 trial

Cerebral Palsy1 trial

Spinal Cord Injury1 trial

Amyotrophic Lateral Sclerosis1 trial

Rheumatoid Arthritis1 trial

References

Drug Info

Quick Facts

Related News